Upfront stereotactic radiosurgery is associated with improved survival in patients with brain metastases from small-cell lung cancer, compared with whole-brain radiation therapy.

Accredited CME from Imedex

This activity features conference chairs Giorgio V Scagliotti, MD, PhD and Luis Paz-Ares, MD, PhD discussing the key take-home points from the European Congress: Perspectives in Lung Cancer.

Conferences

A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient decision-making.

Read More

Hypofractionated radiation therapy is less toxic and just as effective as conventional radiation therapy in patients with non-small cell lung cancer (NSCLC), according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA (September 25-28, 2016).

Read More

Using a web-based application to guide follow-up for patients with advanced lung cancer after they have received initial therapy may improve survival, according to a study presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL).

Read More

A lack of randomized controlled trials (RCTs) shouldn’t rule out the use of effective treatment strategies, such as stereotactic ablative radiotherapy (SABR), for lung cancer, urged a prominent oncologist recently. Instead, comparative-effectiveness research should be viewed as an alternative source of evidence to determine the best treatment strategies for patients with lung cancer.

Read More

News

Upfront stereotactic radiosurgery is associated with improved survival in patients with brain metastases from small-cell lung cancer, compared with whole-brain radiation therapy.
U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation
An immunotherapy plus chemotherapy combination regimen improves overall survival in patients with advanced non-squamous non-small cell lung cancer.
Tyrosine kinase inhibitor treatment is effective in patients with types of epidermal growth factor receptor (EGFR) mutations and advanced lung adenocarcinomas.

Research in Review

A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017; doi:10.1001/jamaoncol.2017.1029).

-----

Realted Content

Read More

A recent budget analysis evaluated the costs, safety, and efficacy of personalized dosing compared with fixed dosing of standard-of-care treatment for non-small cell lung cancer, presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

A patient navigation program implemented in community health centers significantly increased lung cancer screening among underserved populations, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical Oncology (published online May 26, 2017; doi:10.1200/JCO.2016.72.1894).

-----

Related Content

Read More

Resources

The National Comprehensive Cancer Network has made a series of updates to their treatment algorithm for non-small cell lung cancer.

The International Association for the Study of Lung Cancer (IASLC) has published its first version of the Atlas of EGFR Testing in Lung Cancer, which provides up-to-date recommendations on the testing process and interpretation of the results.

Read More

Special Reports

This report will help oncology care providers understand the significance of ALK gene rearrangements for NSCLC as well as the potential benefits of ALK inhibition in relapsed or refractory settings.
Subscribe to Lung Cancer

Ad-Lung Cancer MRC-Desktop Crawler